fldm - FLDM STOCK NEWS

Fluidigm Corporation (NASDAQ:FLDM) announced a study published in Nature Communications, validating its mass cytometry technologies for analyzing immune responses in pregnant women infected with SARS-CoV-2. The research found altered inflammatory markers in infected pregnant women compared to uninfected ones, indicating a unique immune profile. This could improve clinical management of COVID-19 in pregnancy. The study also highlighted the potential role of Fluidigm's technologies in understanding COVID-19, with over 30 peer-reviewed studies utilizing its methods in 2021 alone.

Fluidigm Corporation (Nasdaq: FLDM), a leading biotechnology tools provider, will participate in the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, in Laguna Beach, California. The panel presentation at 8:00 p.m. ET features a customer discussing Fluidigm Imaging Mass Cytometry™ and includes participation from Chris Linthwaite, President and CEO, and Vikram Jog, CFO. Fluidigm develops multi-omic solutions for cancer and immunology, aiming to enhance health insights and therapy effectiveness.

Fluidigm Corporation (Nasdaq: FLDM) reported a 19% increase in total revenue for Q2 2021, totaling $31 million, driven by a rebound in its base business and positive reception of the new CyTOF® XT mass cytometry instrument. Service revenue reached a record $6.6 million, up 29% year-over-year. The company faces ongoing challenges from COVID-19 variant impacts and declining testing revenue, but maintains its full-year revenue guidance of $134-$140 million. Q3 expectations indicate a projected decline in total revenue due to reduced COVID-19 testing contributions.

Fluidigm Corporation (Nasdaq: FLDM) and Ultivue, Inc. have entered into a co-marketing agreement, enhancing their offerings in biomarker discovery and drug development. This collaboration combines Ultivue's InSituPlex^® technology, which facilitates multiplex immunofluorescence imaging, with Fluidigm's Imaging Mass Cytometry™ (IMC™) technology. Researchers will benefit from a seamless workflow that boosts drug discovery efficiency and improves patient stratification in clinical research. Both companies aim to provide comprehensive service capabilities for their clients.

Fluidigm Corporation (NASDAQ: FLDM) announced a collaboration with ImaBiotech to enhance drug development capabilities through Imaging Mass Cytometry™ (IMC™). This partnership solidifies Fluidigm's commitment to advancing high-multiplex imaging technologies, addressing the growing needs of over 200 pharmaceutical clients. The Hyperion™ Imaging System will play a pivotal role in this collaboration, assisting in both product development and service offerings, thereby promoting innovation in clinical and translational research.

Fluidigm Corporation (NASDAQ:FLDM) has announced a co-marketing agreement with Ultivue, Inc. to enhance solutions for biomarker discovery and drug development. This partnership combines Ultivue's InSituPlex® technology and Fluidigm's Imaging Mass Cytometry™ (IMC™), offering researchers comprehensive tools to improve efficiency in clinical and translational research. The Therapeutic Insights Services unit will facilitate access to these technologies, aiming to streamline biomarker discovery processes and enhance health care innovation.

Fluidigm Corporation (Nasdaq:FLDM) will release its second quarter 2021 financial results on August 5, 2021, after market close. President and CEO Chris Linthwaite, along with CFO Vikram Jog, will host a conference call at 2:00 p.m. PT to discuss these results and the company's operational advancements. A press release detailing the financial performance will precede the call. Interested parties can join via provided dial-in numbers or through a live webcast on the Investor Relations page of Fluidigm's website.

Rover Labs, utilizing Fluidigm technology (Nasdaq:FLDM), is conducting a pilot program offering saliva-based COVID-19 testing in approximately 50 NYC public schools. Initiated on June 1, 2021, this initiative aims to facilitate safer in-person learning through mandatory weekly testing. Research indicates that saliva testing is as accurate as traditional nasal swabs, enhancing comfort and reducing costs. The pilot will continue through the summer, leveraging Rover CloudLIS for efficient sample handling and reporting. Key stakeholders emphasize the importance of accessible and non-invasive testing in schools.

Fluidigm Corporation (NASDAQ:FLDM) has launched the CyTOF XT, a new platform aimed at enhancing the profiling of the human immune system. This fourth-generation system simplifies deep cell profiling studies, improves automation, and increases throughput, making it valuable for clinical and translational researchers in pharmaceutical and biotechnology sectors. The CyTOF XT automates processes, reducing hands-on time and costs, and aligns with Fluidigm's Vision 2025 innovation objectives. Initial orders have been secured, highlighting the anticipated demand for this technology.